MOTS-c — Wolverine Health

How it works

Encoded in mitochondrial DNA — not nuclear DNA. That's unusual. It's the first peptide shown to have a mitochondrial genetic origin with systemic metabolic effects. Mouse models show it shifts metabolism toward fat burning and makes cells respond better to insulin — effects that look a lot like what exercise does. Human circulating levels decline with age and metabolic disease. The exercise-mimetic angle is what drives interest. The human evidence base is observational — what we know is that the levels change; what we don't know is whether supplementing them does what it does in mice.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration (obesity and osteoporosis indications).
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

A mitochondrial derived peptide MOTS-c promotes metabolic homeostasis — Lee et al. (2015), Cell Metabolism

MOTS-c, encoded within the mitochondrial 12S rRNA, promotes metabolic homeostasis by regulating glucose uptake and fatty acid metabolism, with circulating levels declining with age in both mice and humans.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on MOTS-c

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where your access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

MOTs-C vs Epitalon: two different bets on ageing slower

WADA

MOTs-C and Epitalon are two very different longevity bets — one on your metabolism, one on the clock inside your cells. Here is what each could do for you, which angle fits your goal, and how far the human proof goes on both.

Mitochondrial-derived peptides: the signals your engines stop sending

Your mitochondria don't just make energy — they send hormone-like signals that tell the body how to run, and the supply fades with age. Mitochondrial-derived peptides are that family. Here's what the class could do, how far proof goes, and where its most-studied member sits in July's FDA review.

MOTS-c: the exercise signal written into your mitochondria

MOTS-c is a tiny peptide your mitochondria release when you train — a signal that tells your body to handle fuel and hold onto strength like a younger one. The early science is genuinely exciting. Here is what it could do for you, and how far the human proof actually goes.

MOTS-c: the newest peptide in the longevity conversation

MOTS-c is a tiny peptide your mitochondria make to help the body handle fuel and hold onto strength — and the level falls with age. Here's the plain-English tour: what it is, what the early science says it might do, and where the July 2026 FDA review just put it.